Table 2.
aPL values and clinical details of the 13 patients with APS
| Study number†† | aPLs | Testing interval | Pregnancy state | Clinical interventions before testing | NPO | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| LA | aβ2GP-1/IU | aCL/IU | ||||||||
| IgG | IgM | IgG | IgM | |||||||
| 001 | IT | 1.58* | 0.24 | 3.42 | 3.73 | 4.51 | Null | Fetal death | No | Term livebirths |
| RT | 1.49* | 0.81 | 10.52 | 3.2 | 1.65 | 13 weeks | Nonpregnant | No | ||
| 1.25* | NA | 8 months | Nonpregnant | LDA | ||||||
| 1.21* | 2.84 | 0.38 | 1.79 | 4.92 | 5 months | Pregnancy-F | LDA + LMWH | |||
| 1.11 | 1.12 | 6.16 | 10.14 | 3.8 | 3 months | Pregnancy-S | LDA + LMWH | |||
| 1.10 | 0.27 | 4.44 | 0.88 | 4.20 | 6 months | Postpartum | No | |||
| 020 | IT | 0.97 | 13.76 | 76.06* | 4.38 | 5.71 | Null | Fetal death | No | Term livebirths |
| RT | NA | 16.51 | 84.66* | 7.90 | 17.25 | 12 weeks | Nonpregnant | No | ||
| NA | 12.74 | 87.57* | 9.02 | 8.54 | 3 months | Pregnancy-F | LDA + LMWH | |||
| 1.05 | 91.19* | 10.78 | 22.38 | 3.68 | 11 months | Postpartum | No | |||
| 1.18 | 39.03* | 130.63* | 6.87 | 45.71* | 5 months | Nonpregnant | LDA | |||
| 1.29* | 70.34* | 77.26* | 15.33 | 16.50 | 5 months | Nonpregnant | LDA + HCQ | |||
| 027 | IT | 1.56* | 6.84 | 49.09* | 4.38 | 2.15 | Null | Fetal death | No | Term livebirths |
| RT | 1.33* | 4.33 | 41.74* | 7.89 | 4.81 | 3 months | Nonpregnant | TDF | ||
| 1.45* | 3.20 | 52.08* | 0.12 | 5.10 | 7 months | Pregnancy-S | TDF + LDA + LMWH | |||
| 1.25* | 2.75 | 21.62* | 1.35 | 2.83 | 4 months | Postpartum | TDF + LMWH | |||
| 1.19 | 4.47 | 10.26 | 0.40 | 1.98 | 4 months | Nonpregnant | TDF | |||
| 1.07 | 4.94 | 21.13* | 1.26 | 6.93 | 12 months | Nonpregnant | TDF | |||
| 036 | IT | 1.11 | 1.94 | 42.02* | 1.02 | 5.92 | Null | Fetal death | LDA + LMWH | Nonpregnant |
| RT | 1.12 | 2.35 | 93.19* | 2.14 | 4.39 | 13 weeks | Nonpregnant | No | ||
| 1.12 | 2.29 | 26.70* | 9.07 | 3.61 | 7 months | Nonpregnant | No | |||
| 1.02 | 0.00 | 22.36* | 0.01 | 2.85 | 14 months | Nonpregnant | No | |||
| 055 | IT | 0.92 | 1.63 | 109.8* | 5.22 | 38.43 | Null | Fetal death | No | Nonpregnant |
| RT | 1.09 | 3.91 | 191.08* | 2.33 | 57.86* | 11 months | Nonpregnant | No | ||
| 1.11 | 1.64 | 180.33* | 3.51 | 58.81* | 4 | Nonpregnant | LDA | |||
| 0.76 | 4.98 | 87.30* | 2.8 | 50.49* | 7 months | Nonpregnant | LDA + HCQ + PNS | |||
| 058 | IT | 1.27* | 2.58 | 36.09* | 1.15 | 46.41* | Null | Fetal death | No | Ongoing |
| RT | 0.99 | 3.88 | 13.10 | 2.11 | 35.35 | 12 weeks | Nonpregnant | No | ||
| 1.21* | 3.17 | 36.65* | 2.48 | 22.03 | 5 weeks | Nonpregnant | No | |||
| 1.01 | 4.69 | 107.38* | 2.5 | 65.39* | 15 months | Pregnancy-F | LDA + HCQ | |||
| 1.13 | 1.93 | 52.83* | 1.57 | 20.15 | 6 months | Pregnancy-T | LMWH + HCQ | |||
| Study number†† | aPLs | Testing interval | Pregnancy state | Clinical interventions | NPO | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| LA | aβ2GP-1/IU | aCL/IU | ||||||||
| IgG | IgM | IgG | IgM | |||||||
| 062 | IT | 1.26* | weakly positive § | Negative § | Null | Fetal death | No | Nonpregnant | Nonpregnant | |
| RT | 1.03 | 5.88 | 37.53* | 3.79 | 3.45 | 12 weeks | Nonpregnant | No | ||
| No | 10.01 | 38.85* | 3.86 | 3.97 | 7 weeks | Nonpregnant | No | |||
| 0.98 | 3.82 | 10.76 | 0.19 | 2.44 | 6 months | Nonpregnant | LDA | |||
| 0.97 | 6.48 | 27.89* | 0.41 | 3.72 | 6 months | Nonpregnant | No | |||
| 063 | IT | 1.19 | 2.04 | 51.8* | 0.08 | 0.11 | Null | Fetal death | No | |
| RT | 1.23* | 3.36 | 38.86* | 5.20 | 5.24 | 12 weeks | Nonpregnant | No | ||
| 1.06 | 4.51 | 30.74* | 2.97 | 6.77 | 5 months | Nonpregnant | No | |||
| 1.04 | 0.07 | 17.24 | 1.06 | 5.19 | 13 weeks | Nonpregnant | LDA | |||
| 1.16 | 5.15 | 81.38* | 2.78 | 50.26* | 6 months | Nonpregnant | LDA + HCQ | |||
| 066 | IT | No | 0.10 | 63.00* | 0.30 | 0.70 | Null | Fetal death | No | NA |
| RT | 0.93 | 2.12 | 30.52* | 2.95 | 4.97 | 12 weeks | Nonpregnant | No | ||
| 080† | IT | 1.11 | 5.03 | 111.50* | 1.79 | 3.74 | Null | Fetal death | LMWH | Term livebirths |
| RT | NA | NA | 71.02* | No | No | 12 weeks | Nonpregnant | No | ||
| 0.98 | 4.31 | 60.87* | 3.17 | 16.33 | 14 weeks | Pregnancy-F | No | |||
| 0.97 | 1.16 | 7.02 | 1.85 | 2.54 | 3 months | Pregnancy-S | LDA + LMWH + HCQ | |||
| 1.08 | 0.00 | 30.93* | 2.67 | 21.41 | 3 months | Pregnancy-T | LMWH + HCQ | |||
| 1.00 | 0.84 | 116.18* | 1.14 | 23.54 | 5 months | Postpartum | HCQ | |||
| 092 | IT | 1.21* | Positive § | Negative § | Null | Fetal death | No | Nonpregnant | Nonpregnant | |
| RT | 1.00 | 2.03 | 77.86* | 0.94 | 9.44 | 4 months | Nonpregnant | No | ||
| 1.11 | 2.64 | 127.5* | 0.11 | 43.84* | 5 months | Nonpregnant | LDA | |||
| 117 ‡ | IT | 1.40 | Positive § | Negative § | Null | Fetal death | No | Ongoing | Ongoing | |
| RT | 1.12 | 1.23 | 76.94* | 1.35 | 25.69 | 4 weeks | Nonpregnant | No | ||
| 1.15 | 1.62 | 50.14* | 1.20 | 17.40 | 4 months | Nonpregnant | LDA + HCQ + MPS | |||
| 1.13 | 1.24 | 51.02 | 1.60 | 23.25 | 5 months | Pregnancy-F | LDA + LMWH + HCQ | |||
| 136 | IT | 1.03 | Positive § | Negative § | Null | Fetal death | No | Nonpregnant | Nonpregnant | |
| RT | 0.93 | 0.00 | 63.81* | 1.37 | 0.77 | 5 months | Nonpregnant | No | ||
aPLs; antiphospholipid antibodies, LA; lupus anticoagulant, aCL; anticardiolipin antibody, aβ2GP1; anti-β2 glycoprotein-1 antibodies, NPO; next pregnancy outcomes, IT; Initial testing, RT; Repeat testing, Pregnancy-F; first-trimester, Pregnancy-S; second trimester, Pregnancy-T; third trimester, LDA; low-dose aspirin, LMWH; low molecular weight heparin, HCQ; hydroxychloroquine, TDF; tenofovir disoproxil fumarate, PNS; prednisone acetate, MPS; methylprednisolone
†† the numbered in chronological order; *and the bold positive results fulfilling the 2006 Sydney criteria; † combined rheumatoid arthritis; ‡ combined Sjögren's syndrome; § the testing method was qualitative